| Identification | Back Directory | [Name]
LSZ-102 | [CAS]
2135600-76-7 | [Synonyms]
LSZ-102
CS-2791
LSZ102;LSZ-102;LSZ 102
2-Propenoic acid, 3-[4-[[2-[2-(1,1-difluoroethyl)-4-fluorophenyl]-6-hydroxybenzo[b]thien-3-yl]oxy]phenyl]-, (2E)- | [Molecular Formula]
C25H17F3O4S | [MDL Number]
MFCD31657401 | [MOL File]
2135600-76-7.mol | [Molecular Weight]
470.46 |
| Chemical Properties | Back Directory | [Boiling point ]
643.5±55.0 °C(Predicted) | [density ]
1.418±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
4.49±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
is a potent, orally bioavailable selective estrogen receptor degrader currently being studied for the treatment of ERα positive breast cancer. | [in vivo]
Treatment of the mice with LSZ-102 once daily at 20 mg/kg results in significant tumor growth inhibition as compare to the control group treated with vehicle alone, resulting in tumor stasis (mean change in tumor volume of LSZ-102 vs control=%ΔT/ΔC of 2.4% on day 48, p<0.05). Dosing of 3 mg/kg solution of LSZ-102 in male Sprague-Dawley rats results in 33% bioavailability and a dose-normalized exposure of 620 nM h[1]. |
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|